RenovoRx Reports First Quarter 2022 Financial Results
RenovoRx (NASDAQ: RNXT) reported financial results for Q1 2022, highlighting significant progress in cancer treatment. The company has $13.1 million in cash, but reported a net loss of $3.0 million, up from $1.1 million the previous year. Research and development costs rose to $1.3 million due to the Phase 3 trial expenses for RenovoGem™, aimed at treating pancreas cancer. The FDA previously granted Orphan Drug Designation for this and other indications, underscoring the potential for improved patient outcomes.
- Cash and cash equivalents at $13.1 million.
- FDA granted Orphan Drug Designation for RenovoGem™.
- Net loss increased to $3.0 million from $1.1 million.
- R&D expenses rose to $1.3 million due to trial costs.
“As we report our Q1 2022 results, we acknowledge that May is Cancer Research Month.
Bagai added, “RenovoRx is at the frontline of cancer research with our late-stage product candidate, RenovoGem™. Later this year, we plan on extending its utility to extrahepatic cholangiocarcinoma (eCCA), a rare and aggressive cancer that forms in bile ducts that lead out of the liver and join with the gallbladder. The FDA granted RenovoRx Orphan Drug Designation for this indication in
Financial Highlights for the Quarter Ended
-
Cash and cash equivalents as of
March 31, 2022 , were$13.1 million -
Research and development expenses were
$1.3 million March 31, 2022 , compared to$0.6 million March 31, 2021 . The increase was due to higher costs incurred on our Phase 3 trial, including consulting, employee and related benefit costs, and an increase in costs for a secondary manufacturer of our RenovoCath® delivery systems. -
General and administrative expenses were
$1.7 million March 31, 2022 , compared to$0.4 million March 31, 2021 . This increase was due to higher employee and related benefits costs, an increase in legal fees reflecting the costs of public company compliance requirements, an increase in professional and consulting services relating to post-IPO support, andDirectors and Officers Liability Insurance . -
Net loss was
$3.0 million March 31, 2022 , compared to net loss of$1.1 million March 31, 2021 . -
As of
March 31, 2022 , the Company had 9,029,305 common shares outstanding.
About the Phase 3 TIGeR-PaC Clinical Trial
TIGeR-PaC is a randomized multi-center Phase 3 study using RenovoRx’s innovative therapy platform, RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion). The study is evaluating the Company’s first product candidate, RenovoGem™, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.
TIGeR-PaC is currently enrolling unresectable LAPC patients at several sites across the US. To learn more about the study and the participating clinical trial sites, visit https://renovorx.com/clinical-trial/.
About
RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven
Learn more by visiting the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding our clinical trials and studies, statements regarding the potential of RenovoTAMP™, RenovoCath® or RenovoGem™ or regarding our ongoing TIGeR-PaC Phase 3 clinical trial in LAPC, and statements regarding the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform, business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; negative impacts of the COVID-19 pandemic on our operations; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the
Forward-looking statements included herein are made as of the date hereof, and
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005148/en/
Company Contact:
Investor Contact:
T:212-896-1254
renovorx@kcsa.com
Media Contact:
T: 206-451-4823
kknightpr@gmail.com
Source:
FAQ
What were RenovoRx's financial results for Q1 2022?
What is RenovoGem™ and its significance?
How much did RenovoRx spend on research and development in Q1 2022?
What is the current status of RenovoRx's clinical trial?
